Consensus Statement revised. (National MS Society).In 1998, the Medical Advisory Board of the National MS Society adopted the "Consensus Statement." For the first time, the Society recommended a treatment--the early use of one of three disease-modifying drugs then approved by the Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) for relapsing-remitting Relapsing-remitting A pattern of symptoms of multiple sclerosis in which symptomatic attacks occur that last 24 hours or more, followed by complete or almost complete improvement. Mentioned in: Multiple Sclerosis MS. In early 2002, when the FDA also approved Rebif (interferon beta-1a interferon beta-1a Avonex, Rebif Pharmacologic class: Biological response modifier Therapeutic class: Antiviral, immunoregulator Pregnancy risk category C Action) for relapsing-remitting MS, the Society's Medical Advisory Board revisited the statement.The revised Consensus Statement adds not only Rebif but also Novantrone Novantrone® Mitoxantrone, see there (mitoxantrone for injection), which is recommended for worsening wors·en tr. & intr.v. wors·ened, wors·en·ing, wors·ens To make or become worse. Noun 1. worsening - process of changing to an inferior state decline in quality, deterioration, declension forms of relapsing-remitting and secondary-progressive MS. A comment advising that the use of these drugs has not been approved for women who are trying to become pregnant, are pregnant, or are nursing has also been added. The revised Consensus Statement is on file at every chapter and on the Society's Web site at nationalmssociety.org. Click the "Treatment" bar on the home page. |
|
||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion